Validation of Time in Range as an Outcome Measure for Diabetes Clinical Trials

Beck, Roy W., Bergenstal, Richard M., Riddlesworth, Tonya D., Kollman, Craig, Li, Zhaomian, Brown, Adam S., Close, Kelly L.·2019·Diabetes Care
DOI 10.2337/dc18-1444

Cited by (792)

Items 601–700 of 792

  1. Understanding Glycemic Variability
    Vedavati Bharat Purandare, Charan Bale, Arjun Lal Kakrani, AG Unnikrishnan · 2021 · Journal of Diabetology
  2. A Framework for Integrating Continuous Glucose Monitor-Derived Metrics into Economic Evaluations in Type 1 Diabetes
    Ágnes Benedict, Emily R. Hankosky, Kinga Marczell, Jieling Chen, David J. Klein, Jaime J. Caro, Jay Patrick Bae, Brian D. Benneyworth · 2022 · PharmacoEconomics
  3. Asthma management: How the guidelines compare
    Tanner J. Nissly · 2022 · The Journal of Family Practice
  4. Study protocol: a randomised controlled proof-of-concept real-world study – does maximising time in range using hybrid closed loop insulin delivery and a low carbohydrate diet restore the glucagon response to hypoglycaemia in adults with type 1 diabetes?
    Faye Baxter, Nicola Baillie, Shareen Forbes · 2022 · BMJ Open
  5. Weight Management Behaviors are Associated with Elevated Glycemic Outcomes in Adolescents and Young Adults with Type 1 Diabetes
    Breana L. Bryant, Christine H. Wang, Maureen C. Monaghan · 2023 · Journal of Clinical Psychology in Medical Settings
  6. Interpretación del monitoreo continuo de glucosa: una visión práctica
    Nicolás Coronel-Restrepo, Alex Ramírez Rincón, Andrés Palacio, María Rocío Delgado, José Fernando Botero · 2023 · Revista Colombiana de Endocrinología Diabetes & Metabolismo
  7. Comprehensive retinal vascular measurements: time in range is associated with peripheral retinal venular calibers in type 2 diabetes in China
    Guohong Zhao, Xiayu Xu, Xinwen Yu, Fei Sun, Aili Yang, Yuxin Jin, Jing Huang, Jing Wei, Bin Gao · 2023 · Acta Diabetologica
  8. Glucose-lowering effects of semaglutide compared with dulaglutide using professional continuous glucose monitoring in outpatients with type 2 diabetes mellitus: a pilot study
    Akira Kurozumi, Yosuke Okada, Momo Saitoh, Yoshiya Tanaka · 2023 · Diabetology International
  9. Carbohydrate counting and insulin analogs to treat type 1 diabetes mellitus. How to improve metabolic control?
    Amanda Maria Barradas Monteiro de Santana, Nathália Azevedo, Raphael Del Roio Liberatore · 2023 · Jornal de Pediatria
  10. Association between extrapolated time in range and large for gestational age infants in pregnant women with type 1 diabetes
    Emily Santos, Tatiana Assunção Zaccara, Cristiane de Freitas Paganoti, Stela Verzinhasse Peres, Rossana Pulcineli Vieira Francisco, Rafaela Alkmin da Costa · 2024 · Journal of Diabetes and its Complications
  11. Evaluating the efficacy and safety of weekly Insulin Icodec vs. Daily Insulin Glargine in type 2 Diabetes Mellitus: a systematic review and meta-analysis
    Varisha Zuhair, Muhammad Adil Obaid, Muhammad Saqlain Mustafa, Muhammad Ashir Shafique, Burhanuddin Sohail Rangwala, Areej Shakil, Areesha Babar, Hussain Sohail Rangwala, Muhammad Ishtiaq Obaid · 2024 · Journal of Diabetes & Metabolic Disorders
  12. Perspectives and Behaviors of People with Diabetes toward Time in Range and Glucose Control in Diabetes Management: An Online Survey
    Christophe E.M. De Block, ALICE Y.Y. CHENG, Gayathri Anil, John Michael D’Cruz, Anna Ginovker · 2024 · Diabetes Therapy
  13. Ultra-long-acting insulin: a new chapter in diabetes therapy?
    Muhammad Ali Karamat, Srikanth Bellary, Anthony H Barnett · 2024 · The Lancet Diabetes & Endocrinology
  14. EFFECTIVENESS OF HYBRID CLOSED-LOOP SYSTEMS IN PEDIATRIC TYPE 1 DIABETES MELLITUS MANAGEMENT: A SYSTEMATIC REVIEW
    Justyna Grudziąż-Sękowska, Kuba Bartłomiej Sękowski, Zuzanna Grześczyk-Nojszewska, Jarosław Pinkas, Janusz Ostrowski, Mateusz Jankowski · 2025 · Health Problems of Civilization
  15. Relation of time in range to severity of coronary artery disease in patients with type 2 diabetes: A cross-sectional study
    Weiguo Ma, Jinfeng Li, Xiaojuan Shao, Xiaohong Yin, Chuanqing Xie, Fenfen Wang, Ya Li · 2025 · Open Medicine
  16. Meta-analysis of the epidemiology of microvascular complications in people with Type 2 diabetes in mainland China
    Cheng Yuan-yuan, QU Shuli, LIU Yanjun, Zhang Yuqi, Wenjie Xu, Chen Li · 2020 · Global Journal of Obesity Diabetes and Metabolic Syndrome
  17. Adjustment of Insulin Therapy: New Insights from Continuous Glucose Monitoring
    Tae Jung Oh · 2020 · Journal of Korean Diabetes
  18. Diabetic Kidney Disease: Identification, Prevention, and Treatment
    M. L. Caramori, Peter R Rossing · 2022 · Springer eBooks
  19. Can exenatide flatten the post-prandial glucose curve in type 1 diabetes?
    Charlotte K. Boughton, Roman Hovorka · 2020 · Annals of Translational Medicine
  20. New glucose metrics do not associate with carotid artery wall thickness and endothelial function in type 1 Diabetes
    Antonio Cutruzzolà, Concetta Irace, Martina Parise, Raffaella Fiorentino, Milena Barone, Agostino Gnasso · 2020
  21. News and Views: Update on technologies, medicines and treatments
    Simon O’Neill · 2019 · Diabetic Medicine
  22. Closed-Loop-Insulin-Therapie bei Patienten mit Typ-1-Diabetes
    Isabel N. Schellinger · 2020 · Der Diabetologe
  23. Sepsis prediction model derived from hospital-arrival clinical data
    Fran Balamuth · 2020 · The Journal of Pediatrics
  24. The insulin pump therapy in type 1 Diabetes: The importance of glucose variability
    Jovan Jozić, Milan Bjelica, Katarina S. Lalic · 2019 · Medicinski podmladak
  25. Cambios en la hemoglobina glucosilada antes y después de utilizar monitoreo de glucosa intersticial intermitente
    Bárbara J. Staltari, Florencia G. Cutó, Romina Ivana Benkovic, Santiago De Loredo, Luis De Loredo · 2020 · Alad
  26. Continuous glucose monitoring: Musing on our progress in memory of Dr Andrew Jay Drexler
    G. Grunberger · 2020 · Journal of Diabetes
  27. «TIME IN RANGE» INDICATOR DEPENDING ON THE DEGREE OF VIOLATIONS OF THE GLUCOSE CONTROL SYSTEM
    S. A. Mustafaeva · 2020 · Bulletin of Problems Biology and Medicine
  28. Veränderungen im Verbrauch von Blutzuckerteststreifen bei Patienten in Deutschland, die FGM-Systeme anwenden
    Karel Kostev, Louisa van den Boom · 2020 · Monitor Versorgungsforschung
  29. Cost-Effectiveness of Monitoring Metabolic Control
    Ivica Smokovski · 2020 · Springer eBooks
  30. Glucose values prediction five years ahead with a new framework of missing responses in reproducing kernel Hilbert spaces, and the use of continuous glucose monitoring technology
    Marcos Matabuena, Paulo Félix, Carlos Meijide-Garcia, Francisco Gudé · 2020 · arXiv (Cornell University)
  31. Association of Body Fat Percentage With Time in Range Generated by Continuous Glucose Monitoring During Intensive Insulin Pump Therapy in Type 2 Diabetes
    Yuting Ruan, Jiana Zhong, Rongping Chen, Zhen Zhang, Dixing Liu, Jia Man Sun, Hong Chen · 2021 · Research Square
  32. New Trends: Time in Range and the Use of Continuous Glucose Monitoring Devices on Glycemic Control
    Karyna Lucena Valença De Souza, Marcela Mascarenhas Braga Rassi, Diana Aristótelis Rocha de Sá, Renata Maksoud Bussuan, Luciana Corrêa de Souza Rodrigues, Alberto Krayyem Arbex · 2021 · European Journal of Medical and Health Sciences
  33. Methoden der Stoffwechselkontrolle – HbA1c versus „time in range“
    Guido Freckmann, Sina Buck, Delia Waldenmaier, Cornelia Haug · 2021 · Der Diabetologe
  34. The Kidney in Type I Diabetes
    Maria Loredana Marcovecchio, Nektaria Papadopoulou‐Marketou · 2021 · Springer eBooks
  35. REAL-WORLD OBSERVATIONAL STUDY REGARDING GLUCOSE CONTROL IN INSULIN TREATED DIABETES MELLITUS PATIENTS. GLUCOSE VARIABILITY PATTERNS ANALYSIS USING CONTINUOUS GLUCOSE MONITORING SYSTEM (CGMS)
    Mihaela Simona Popoviciu · 2021 · FARMACIA
  36. Neue Entwicklungen bei Diabetes mellitus Typ 1
    Linus Haberbosch, Joachim Spranger · 2021 · DMW - Deutsche Medizinische Wochenschrift
  37. Continuous and Intermittent Glucose Monitoring in 2020
    Bruce W. Bode, Tadej Battelino, Klemen Dovč · 2021 · Diabetes Technology & Therapeutics
  38. Association Between Time in Range and HbA1c in Japanese Patients With Type 2 Diabetes Mellitus
    Akira Kurozumi, Yosuke Okada, Tomoya Mita, Satomi Wakasugi, Naoto Katakami, Hidenori Yoshii, Kazuko Kanda, Keiko Nishida, Shinichiro Mine, Yoshiya Tanaka et al. · 2021 · Research Square
  39. Epigenetic Remodeling in an IMR-32 Cell Line and Transgenic Mouse Model of Alzheimer's Disease
    Matthew S Baker · 2014 · Digital Commons (Liberty University)
  40. The Importance of Time in Range (TIR) for Continuous Glucose Monitoring (CGM) in the Clinical Practice for Diabetes
    Hiroshi Bando · 2021 · Edelweiss Journal of Biomedical Research and Review
  41. Evaluation of the Association of CGM Metrics with Antihyperglycemic Drugs in Insulin-Treated Diabetics
    Toshiyuki Horiuchi, Junichiro Adachi, Yoshihiro Sekiguchi, Akiko KANAMARU · 2021 · Dubai Diabetes and Endocrinology Journal
  42. Does HbA1c Remain the Most Important Therapeutic Target in Outpatient Management of Diabetes?
    Kristen M. Gonzales, Steve Smith · 2021 · Wiley eBooks
  43. Interpretation of Continuous Glucose Monitoring and Time in Range and Glycemic Control
    Dorothy J. Becker · 2020 · Central European Annals of Clinical Research
  44. A Comprehensive Analysis of Glycemic Variability and Time in Ranges Assessed using CGM in Diabetic People with diabetes with Microvascular Complications: A Single-Center Retrospective Real-World Evidence Study on Indian Population
    Mudit, Srivani Palukuri, Saurav Deka · 2022 · British journal of healthcare and medical research
  45. Assessment of the Effect of Timing of Insulin Glargine Administration (Bedtime versus Morning) on Glycemic Control in Children with Type 1 Diabetes in Cairo, Egypt: A Single Centre Experience
    Marise Abdou, Radwa Ahmed Shamma, Ghada Mohammad Anwar, Noha Musa, Marwa Farouk Mira · 2022 · Current Diabetes Reviews
  46. Peer Review #2 of "Intestinal fatty acid-binding protein, a biomarker of intestinal barrier dysfunction, increases with the progression of type 2 diabetes (v0.2)"
    2021 · PeerJ
  47. News and Views: Update on technologies, medicines and treatments
    Simon O’Neill · 2019 · Diabetic Medicine
  48. Peer Review #2 of "Intestinal fatty acid-binding protein, a biomarker of intestinal barrier dysfunction, increases with the progression of type 2 diabetes (v0.1)"
    2021 · PeerJ
  49. Peer Review #3 of "Intestinal fatty acid-binding protein, a biomarker of intestinal barrier dysfunction, increases with the progression of type 2 diabetes (v0.1)"
    2021 · PeerJ
  50. Dapagliflozin as an Adjunct Therapy to Insulin in Patients with Type 1 Diabetes Mellitus: Efficacy and Safety of this Combination
    JOHAN H. JENDLE, Francisco Javier Ampudia‐Blasco, Martin Füchtenbusch, Paolo Pozzilli · 2021 · touchREVIEWS in Endocrinology
  51. Peer Review #1 of "Intestinal fatty acid-binding protein, a biomarker of intestinal barrier dysfunction, increases with the progression of type 2 diabetes (v0.1)"
    2021 · PeerJ
  52. Kommentar zu Kontinuierliche Glukosemessung: am besten dauerhaft beibehalten!
    Robert A. Ritzel · 2022 · Diabetologie und Stoffwechsel
  53. The role Time in range depending on the method of assessing glycemic control in diabetes: A review
    Л. А. Суплотова, Судницына Анна Сергеевна, Душина Татьяна Сергеевна · 2022 · Consilium Medicum
  54. Devices
    David Carty · 2022 · Wiley eBooks
  55. Population-level impact and cost-effectiveness of continuous glucose monitoring and intermittently-scanned continuous glucose monitoring technologies for adults with type 1 diabetes in Canada: a modelling study
    Michael Anthony Rotondi, Octavia C. Y. Wong, Michael Charles Riddell, Bruce A. Perkins · 2022
  56. Population-level impact and cost-effectiveness of continuous glucose monitoring and intermittently-scanned continuous glucose monitoring technologies for adults with type 1 diabetes in Canada: a modelling study
    Michael Anthony Rotondi, Octavia C. Y. Wong, Michael Charles Riddell, Bruce A. Perkins · 2022
  57. Time in range: new parameter to evaluate blood glucose control
    Milan Flekač · 2022 · Vnitřní lékařství
  58. The Kidney in Type I Diabetes
    Maria Loredana Marcovecchio, Nektaria Papadopoulou‐Marketou · 2022 · Springer eBooks
  59. Reduktion von diabetesbezogenem Distress bei Typ-1- und Typ-2-Diabetes durch eine kognitiv-verhaltenstherapeutische Gruppenintervention
    Lara K. Gomille, Jennifer Grammes, Judith Lehnart, Christine Binz, Sandra Koehn, Thomas Kubiak, Andrea Benecke · 2022 · Diabetologie und Stoffwechsel
  60. Hypoglycemia unawareness identified by continuous glucose monitoring system is frequent in outpatients with type 2 diabetes without receiving intensive therapeutic interventions
    Bingkun Huang, Qiuhui Jiang, Ting Wu, Qingbao Shen, Wengui Wang, Shoubi Wang, Yinxiang Huang, Shunhua Wang, Peiying Huang, Mingzhu Lin et al. · 2022 · Research Square
  61. „Time in range“ (TIR) vs. Glykohämoglobin Typ A1c (HbA1c): was zählt für unsere Patienten?
    Clemens Harer, Julia Katharina Mader · 2022 · Die Diabetologie
  62. Diabete hi-tech
    Martina D’Agostin, Cristina Tumminelli, Veronica Grigoletto, Gianluca Tornese, Egidio Barbi, Elena Faleschini · 2022 · Medico e Bambino
  63. Accuracy of the Contour® Next Link 2.4 blood glucose monitoring system in Japanese individuals: a single-center study
    Takeshi Katsuki, Yuko Kondo, Masataka Fujita, Hajime Tanaka, Rina Suzuki, Hiroko Takeda, Toshihide Kawai · 2022 · Diabetology International
  64. Make room for continuous glucose monitoring in type 2 diabetes management
    Kevin T. Schleich · 2022 · The Journal of Family Practice
  65. Uso de microinfusor de insulina con sistema integrado en pacientes pediátricos con diabetes tipo 1: resultados metabólicos iniciales
    Carolina Wong Lam, Josefa Hurtado Navarro, Rocío Fuentes Díaz, Elizabeth Toro Toro, Bárbara Reyes Espejo · 2022 · Andes pediatrica
  66. Interpretación de los informes glucométricos (sistemática de interpretación, AGP, LibreView, LibreLink)
    Ángeles Beatriz Álvarez Hermida, Fernando Gallo Trébol · 2022 · Diabetes práctica
  67. Type 1 diabetes mellitus and cardiovascular risk: A short review
    Konstantinos Kitsios, Christina Trakatelli, Maria Sarigianni, Αnastasia Kyriazidou, Fotios Aroutsidis, Κonstantinos Mastrogiannis, Vasilios Kotsis · 2022 · Journal of Atherosclerosis Prevention and Treatment
  68. Delaying the Onset and Progression of CKD in People with Diabetes: Technology and Effectiveness in Achieving Glucose Control
    Alaa Kubbar, Hussam R Alkaissi, Mary Ann Banerji · 2022 · Springer eBooks
  69. Control of Blood Glucose and Cardiovascular Risk Profile
    Stefano Ciardullo, Gianluca Perseghin · 2023 · Updates in hypertension and cardiovascular protection
  70. Type 1 diabetes mellitus – Population characterization and metabolic control outcomes in a Portuguese patient sample
    Juliana da Silva Cardoso, Paula Manuel Vieira, Ana De Carvalho Vaz, Sílvia Santos Monteiro, Luís Ribeiro, Catarina Mendes, Joana Freitas, Carla Rocha, Maria João Oliveira, Teresa Borges · 2023 · Primary care diabetes
  71. Kommentar zu: „Estimated Time in Range“ mit mikrovaskulären Komplikationen assoziiert?
    Ralph Ziegler · 2023 · Diabetologie und Stoffwechsel
  72. Differences in glycemic control in type 1 diabetes children and adolescents : in a national and international perspective and the effect on microvascular complications in young adults
    Johan Anderzén · 2023 · Linköping University medical dissertations
  73. Eine neue Welt: Verbesserung der Diabetestherapie durch digitale und technische Innovationen
    Markus Menzen · 2023 · DMW - Deutsche Medizinische Wochenschrift
  74. Kosteneffektivität der Überwachung der metabolischen Kontrolle
    Ivica Smokovski · 2023 · Springer eBooks
  75. Letter by Deng et al Regarding Article, “Risk of Macrovascular and Microvascular Disease in Diabetes Diagnosed Using Oral Glucose Tolerance Test With and Without Confirmation by Hemoglobin A1c: The Whitehall II Cohort Study”
    Liling Deng, Yan Chen, Wuquan Deng · 2023 · Circulation
  76. Can continuous glucose monitoring be used as a new tool for diagnosing white coat hyperglycaemia and possibly some other entities?
    Milovan Stojanović, Milica Pešić, Stevan Ilić, Marina Deljanin-Ilić, Vojislav M. Ćirić · 2022 · AFMN Biomedicine
  77. The effects of dapagliflozin on the neovascularization of carotid atherosclerosis plaques in type 2 diabetes mellitus patients
    Juanjuan Li, Ying Xin, Fang Wang, Xiaoyun Dong, Lili Xu · 2023 · Pakistan Journal of Pharmaceutical Sciences
  78. Continuous Glucose Monitoring-Assisted Insulin Dose Titration in the Indian Outpatient Setting
    Sri Ramya Ganti, Kalyan Chakravarthy Gurazada · 2022 · International Journal of Diabetes and Technology
  79. Perfil clínico e laboratorial das crianças e adolescentes com diabetes mellitus: experiência de um centro terciário
    Amanda Maria Barradas Monteiro de Santana · 2022
  80. Trends in Time in Range–Related Publications and Clinical Trials: A Bibliometric Review
    Pranav M. Patel, Richard M. Abaniel, Natasha Dogra, Charles B. Lo, Marie A. Frazzitta, Naunihal S. Virdi · 2023
  81. Trends in Time in Range–Related Publications and Clinical Trials: A Bibliometric Review
    Pranav M. Patel, Richard M. Abaniel, Natasha Dogra, Charles B. Lo, Marie A. Frazzitta, Naunihal S. Virdi · 2023
  82. Case Reports Using Continuous Glucose Monitoring: Analysis For Application Of Digitalization In Management Of Diabetes Mellitus
    Rajesh K. Saxena, Anurupa B Singh, Dr. N. P .Singh · 2023 · International Journal of Life Science and Pharma Research
  83. Importance of continuous glucose monitoring in the treatment of diabetes mellitus
    Sun Joon Moon, Won‐Young Lee · 2023 · Journal of Korean Medical Association
  84. Association of Time in Range with Cognitive Impairment in Type 2 Diabetic Patients
    Yanting Liu, Yanlan Liu, Hui-Na Qiu, Nahal Haghbin, Jingbo Li, Yaoshuang Li, Weiran Jiang, Longfei Xia, Fan Wu, Chen-Ying Lin et al. · 2023 · Research Square
  85. Association of GA/HbA1c Ratio with Diabetic Retinopathy
    Tianyao Zhang, Zheng Xu · 2023 · International Journal of Clinical Medicine
  86. Effects of fixed-dose mitiglinide/voglibose combination on vascular endothelial function and glycemic variability in patients with type 2 diabetes: A randomized controlled trial
    Kenichi Tanaka, Yosuke Okada, Saeko Umezu, Ryoma Hashimoto, Yukiko Tomoyose, Rina Tateyama, Yuri Hori, Momo Saito, Akemi Tokutsu, Satomi Sonoda et al. · 2023 · Research Square
  87. The Effect of Insulin Degludec Versus Insulin Glargine U100 on Glucose Metrics Recorded During Continuous Glucose Monitoring in People With Type 1 Diabetes and Recurrent Nocturnal Severe Hypoglycemia
    Julie Maria Bøggild Brøsen, Rikke Mette Agesen, Amra Ciric Alibegovic, Henrik Ullits Andersen, Henning Beck‐Nielsen, Peter Gustenhoff, Troels Krarup Hansen, Christoffer Hedetoft, Tonny Joran Jensen, Claus Bogh Juhl et al. · 2023 · Journal of Diabetes Science and Technology
  88. CLINICAL BENEFIT OF USING CONTINUOUS MONITORING OF BLOOD GLUCOSE LEVELS IN PATIENTS WITH TYPE 2 DIABETES
    Valentyna I. Velychko, Yе. O. Tuliantseva, Г. О. Данильчук, O. O. Shapovalov · 2023
  89. WITHDRAWN: Once-Weekly Insulin Icodec vs Once-Daily Insulin Glargine U100 for type 2 diabetes in insulin naive patients: a systemic review and meta-analysis
    Faiza Zakaria, Ahmed Kunwer Naveed, Mushood Ahmed, Rameen Rao, Areeba Tufail Shaikh, Anusha Abdul Muqeet Farid, Tehreem Ali, Muhammad Hasanain · 2023 · Diabetes Epidemiology and Management · Retracted
  90. Redefining Diabetes Strategies in Primary Care: Four New Pillars of Management
    Akshay Jain · 2023 · Canadian Primary Care Today
  91. Satisfaction with Home Healthcare Provider Service in Adults with Type 1 Diabetes Using a Hybrid Closed Loop System: The SATURN Study
    Hélène P. Hanaire, Nicolas Naïditch, Vincent Melki, Pierre Morcel, Nelly Puech-Bret, Emeric Scharbarg, Raquel Tirado Godàs, Guila Lancman, Manuella Schaller, Cécile Delval et al. · 2023 · EMJ Diabetes
  92. Association of point in range with β-cell function and insulin sensitivity of type 2 diabetes mellitus in cold areas
    Yanan Ni, Dan Liu, Xiaona Zhang, Hong Yan Qiao · 2023 · Frigid Zone Medicine
  93. Positioning “Time-in-Range” in the Treatment of Diabetes in India
    Viswanathan Mohan, Ambika G. Unnikrishnan, Jothydev Kesavadev, Banshi Saboo · 2022 · International Journal of Diabetes and Technology
  94. You may delay, but time will not. Beta cells lost are never found again: a case for timely initiation of basal insulin in type 2 diabetes
    Susan Renda, Jeffrey S. Freeman · 2024 · Postgraduate Medicine
  95. Bibliometric Insight into Continuous Glucose Monitoring in Diabetes Glycemic Control: Research Structure and Hotspots Evolution
    Duo Zhang, Yaqin Yang, Jiaqi Zhang, Junhui Chen, Lihua Huang, Lei Zhang, Xusheng Liu · 2024 · SSRN Electronic Journal
  96. Flash glucose monitoring in diabetes
    Annel Lameijer · 2024 · University of Groningen research database (University of Groningen / Centre for Information Technology)
  97. Improvement in Glycemic Indices and Point in Range by Addition or Switch to IDegAsp–Real-World Evidence
    Krishna Seshadri, Subhadra Polisetti, Surekha Tippisetty · 2024 · Journal of Diabetology
  98. First experiences of using the Dexcom ONE CGM system: results from a national survey on the perception of early adopters
    Andrea Boaretto, Dario Pitocco · 2024 · AboutOpen
  99. Impact of Comprehensive Geriatric Assessment and Intervention on Glycemic Control in Elderly Diabetic Patients
    映薇 常 · 2024 · Advances in Clinical Medicine
  100. Impacto del inicio de la monitorización flash de glucosa en pacientes adultos con diabetes tipo 1
    Rebeca Jiménez Sahagún · 2024 · UVaDOC UVaDOC University of Valladolid Documentary Repository (University of Valladolid)